BR9710615A - Use of an agent in the manufacture of a medication for the treatment of bone metabolic disease, and, bone anti-absorption agent. - Google Patents

Use of an agent in the manufacture of a medication for the treatment of bone metabolic disease, and, bone anti-absorption agent.

Info

Publication number
BR9710615A
BR9710615A BR9710615-1A BR9710615A BR9710615A BR 9710615 A BR9710615 A BR 9710615A BR 9710615 A BR9710615 A BR 9710615A BR 9710615 A BR9710615 A BR 9710615A
Authority
BR
Brazil
Prior art keywords
mmp
bone
agent
manufacture
metabolic disease
Prior art date
Application number
BR9710615-1A
Other languages
Portuguese (pt)
Inventor
Niels Taekerr Foged
Jean-Marie Delaisse
Morten Meldal
Original Assignee
Center For Clinical & Basic Re
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Center For Clinical & Basic Re filed Critical Center For Clinical & Basic Re
Publication of BR9710615A publication Critical patent/BR9710615A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

''USO DE UM AGENTE NA MANUFATURA DE UM MEDICAMENTO PARA O TRATAMENTO DE DOENçA METABóLICA óSSEA, E, AGENTE DE ANTI-ABSORçãO óSSEA''. A doença metabólica óssea é tratada pela inibição da produção ou açaõ da metaloproteinase de matriz tipo membrana (MT-MMP) ou da metaloproteina de matriz 12 (MMP-12) envolvida na atividade reabsortiva dos osteoclastos. Os inibidores para a MT-MMP e MMP-12 e a atividade da metaloproteinase associada à membrana incluem pepíteos e anólogos de peptídeos gerados usando-se uma coleção de contas PEGA, agentes de ácido nucleico antissentido e anticorpos. As proteinases MT1-MMP e MMP-12 são constatadas serem expressas em osteoclastos e podem ser seletivamente inibidas.'' USE OF AN AGENT IN THE MANUFACTURE OF A MEDICINE TO TREAT BONE METABOLIC DISEASE AND BONE ANTI-ABSORPTION AGENT ''. Metabolic bone disease is treated by inhibiting the production or action of membrane-type matrix metalloproteinase (MT-MMP) or matrix metalloprotein 12 (MMP-12) involved in the resorptive activity of osteoclasts. Inhibitors for MT-MMP and MMP-12 and membrane-associated metalloproteinase activity include peptides and peptide analogs generated using a collection of PEGA beads, antisense nucleic acid agents and antibodies. Proteinases MT1-MMP and MMP-12 are found to be expressed in osteoclasts and can be selectively inhibited.

BR9710615-1A 1996-07-30 1997-07-29 Use of an agent in the manufacture of a medication for the treatment of bone metabolic disease, and, bone anti-absorption agent. BR9710615A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9615976.9A GB9615976D0 (en) 1996-07-30 1996-07-30 The use of proteinase inhibitors for the prevention or reduction of bone resorption
PCT/EP1997/004110 WO1998004287A1 (en) 1996-07-30 1997-07-29 The use of proteinase inhibitors for prevention or reduction of bone resorption

Publications (1)

Publication Number Publication Date
BR9710615A true BR9710615A (en) 2000-01-11

Family

ID=10797737

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9710615-1A BR9710615A (en) 1996-07-30 1997-07-29 Use of an agent in the manufacture of a medication for the treatment of bone metabolic disease, and, bone anti-absorption agent.

Country Status (9)

Country Link
EP (1) EP0915709A1 (en)
JP (1) JP2001501594A (en)
CN (1) CN1226174A (en)
AU (1) AU733104B2 (en)
BR (1) BR9710615A (en)
CA (1) CA2261567A1 (en)
GB (1) GB9615976D0 (en)
IL (1) IL128103A0 (en)
WO (1) WO1998004287A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061623A1 (en) * 1999-04-09 2000-10-19 Human Genome Sciences, Inc. 62 human secreted proteins
US6277061B1 (en) 1998-03-31 2001-08-21 The Research Foundation Of State University Of New York Method of inhibiting membrane-type matrix metalloproteinase
US6352976B1 (en) 1998-12-31 2002-03-05 Aventis Pharmaceuticals Inc. Selective inhibitors of MMP-12
CA2356919A1 (en) * 1998-12-31 2000-07-13 Michael J. Janusz Selective inhibitors of mmp-12
FR2802945A1 (en) * 1999-12-28 2001-06-29 Pf Medicament New nucleic acid encoding matrix metalloprotease-25, useful for treatment and diagnosis of cancer, angiogenesis and inflammation
AU2001252278A1 (en) 2000-04-05 2001-10-15 Ipf Pharmaceuticals Gmbh Medicament containing a tissue inhibitor of metalloproteinases-2 (timp-2) as an osteo-anabolically active substance
EP1288297A4 (en) * 2000-05-19 2004-11-17 Daiichi Fine Chem Co Ltd Regulation of mt1-mmp activity
US7094754B2 (en) 2001-08-16 2006-08-22 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
US7071164B2 (en) 2001-08-16 2006-07-04 Kimberly-Clark Worldwide, Inc. Anti-cancer and wound healing compounds
US6906036B2 (en) 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
US7186693B2 (en) 2001-08-16 2007-03-06 Kimberly - Clark Worldwide, Inc. Metalloproteinase inhibitors for wound healing
EP1531833A1 (en) * 2002-07-18 2005-05-25 Index Pharmaceuticals AB Antisense compounds, methods and compositions for treating mmp-12 related inflammatory disorders
US7148194B2 (en) 2002-12-30 2006-12-12 Kimberly-Clark Worldwide, Inc. Method to increase fibronectin
US7189700B2 (en) 2003-06-20 2007-03-13 Kimberly-Clark Worldwide, Inc. Anti-chrondrosarcoma compounds
WO2007079218A2 (en) 2005-12-30 2007-07-12 Dyax Corp. Metalloproteinase binding proteins
AU2008338421A1 (en) * 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins
EP2262530A4 (en) * 2008-03-03 2012-12-05 Dyax Corp Metalloproteinase 12 binding proteins
US10314909B2 (en) 2011-10-21 2019-06-11 Dyax Corp. Combination therapy comprising an MMP-14 binding protein
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
KR101576904B1 (en) * 2014-07-31 2015-12-14 (주)케어젠 Peptides Having Activities for Inhibiting Differentiation and Activity of Osteoclast and Uses Thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2848232B2 (en) * 1993-02-19 1999-01-20 武田薬品工業株式会社 Aldehyde derivatives
WO1995015374A1 (en) * 1993-11-30 1995-06-08 Fuji Yakuhin Kogyo Kabushiki Kaisha Novel metalloprotease and dna coding for the same

Also Published As

Publication number Publication date
CN1226174A (en) 1999-08-18
JP2001501594A (en) 2001-02-06
GB9615976D0 (en) 1996-09-11
CA2261567A1 (en) 1998-02-05
EP0915709A1 (en) 1999-05-19
AU4203297A (en) 1998-02-20
IL128103A0 (en) 1999-11-30
WO1998004287A1 (en) 1998-02-05
AU733104B2 (en) 2001-05-10

Similar Documents

Publication Publication Date Title
BR9710615A (en) Use of an agent in the manufacture of a medication for the treatment of bone metabolic disease, and, bone anti-absorption agent.
ATE241365T1 (en) PREPARATIONS CONTAINING SACCHARIDE FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSES
PT698108E (en) ADENOVATIVE VECTORS OF ANIMAL ORIGIN AND USES IN GENE THERAPY
RU94027680A (en) Parathyroid hormone and raloxifen for bone mass increase, pharmaceutical composition and method of osseous mass increase
BRPI0108977B8 (en) azacyclic compounds, pharmaceutical composition and use of a compound or pharmaceutically acceptable salt thereof
BR0009042A (en) Compound, use of the same, process to prepare a compound, pharmaceutical composition, and methods to treat a disease in an animal in which the activity of cysteine protease contributes to the pathology and / or symptomatology of the disease, and to treat a disease in an animal in which the activity cathepsin s contributes to the pathology and / or symptom of the disease
BR0014525A (en) Process of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
ATE322283T1 (en) TRANSDERMAL USE OF SECRETIN TO TREAT AUTISM
ES2133785T3 (en) METALOPROTEINASE INHIBITORS.
PT913156E (en) USE OF PROTEIN C ACTIVATED TO TREAT HYPERCERAGULATE STATES ASSOCIATED WITH SEPSIA
DE69914084D1 (en) PHENYLACETYLGLUTAMINE, PHENYLACETYLISOGLUTAMINE, AND / OR PHENYLACETATE FOR TREATING NEOPLASTIC DISEASES
BR9807796A (en) Processes to treat urinary incontinence, vertigo and motion sickness, and pharmaceutical composition.
MXPA04003773A (en) Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment.
BR0010983A (en) Preparations for the application of anti-inflammatory agents
Rowan et al. Debridement of experimental full-thickness skin burns of rats with enzyme fractions derived from pineapple stem
BR0212249A (en) Compound, pharmaceutical composition, method of treatment or prophylaxis of diseases, and use of a compound
ES2211996T3 (en) UNION AGENTS FOR HIALURONIC ACID RECEPTORS AND THEIR USE FOR TUMOR TREATMENT OR RESISTANCE.
YU60199A (en) New bpc peptide salts with organo-protective activity,the process for their preparation and their use in therapy
GT199900171A (en) ORAL SERTRALINE CONCENTRATE.
FI961494A0 (en) Pharmaceutical compositions and their use, in particular for the treatment of neurodegenerative diseases
ATE270110T1 (en) MEDICINAL PRODUCT CONTAINING TISSUE INHIBITOR OF METALLOPROTEINASES-2 (TIMP-2) AS AN OSTEOANABOLIC SUBSTANCE
KR950704358A (en) Cathepsin L specific inhibitory polypeptide
ID24561A (en) APPLICATION OF OLIGOMERIC CARDILAJ MATRIX PROTEIN TO TREAT REMATOID ARTRITIS
BR9914570A (en) Process for the treatment of schizophrenia as well as agents for use in this process
BR0200291A (en) Liquid pharmaceutical composition for use in treating bone diseases, process for preparing same and process for treating bone disease

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]